[1
]
From the South African Medical Research Council Vaccines and Infectious Diseases Analytics
Research Unit (S.A.M., V.B., A.L.K., G.K., S.B., J.P., A.J., M.L., S.M., A.M., C.T.,
A.T., A.I.), African Leadership in Vaccinology Expertise (C.L.C.), Wits Reproductive
Health and HIV Institute (L.F., E.H., M. Masenya, F.P., S.E.), the Antibody Immunity
Research Unit, School of Pathology (J.N.B., C.K.W., P.L.M.), and the Perinatal HIV
Research Unit (C.B.), Faculty of Health Sciences, and the Department of Science and
Innovation/National Research Foundation South African Research Chair Initiative in
Vaccine Preventable Diseases Unit (S.A.M., V.B., A.L.K., G.K., S.B., A.I.), University
of the Witwatersrand, and the National Institute for Communicable Diseases (NICD)
of the National Health Laboratory Service (NHLS) (J.N.B., C.K.W., P.L.M.), Johannesburg,
Setshaba Research Centre, Tshwane (S.D.P., K.A., M. Malahleha, M. Masilela, K.M.),
the Division of Pulmonology, Groote Schuur Hospital and the University of Cape Town
(K.D., A.E., S.O.), and the Family Centre for Research with Ubuntu, Department of
Paediatrics, University of Stellenbosch (S.L.B., M.G., L.R.), Cape Town, Soweto Clinical
Trials Centre, Soweto (Q.E.B., A.E.B.), and the Africa Health Research Institute (S.-H.H.,
H.R., A.S.) and the KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP),
University of KwaZulu-Natal (S.P., H.T., T.O., A.S.), Durban - all in South Africa;
the Oxford Vaccine Group, Department of Paediatrics (M.V., P.A., S.R., A.J.P.), and
Jenner Institute, Nuffield Department of Medicine (T.L., S.G.), University of Oxford,
Oxford, the Faculty of Infectious and Tropical Diseases, Department of Immunology
and Infection, London School of Hygiene and Tropical Medicine, London (K.D., A.E.),
Division of Infection and Immunity, University College London, London (K.D.), and
AstraZeneca Biopharmaceuticals, Cambridge (N.M.D., E.J.K., T.L.V.) - all in the United
Kingdom; and Max Planck Institute for Infection Biology, Berlin (S.-H.H., H.R.).